Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2011 Oct 19;13(1):60.
doi: 10.1186/1532-429X-13-60.

Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance

Affiliations
Comparative Study

Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance

Kan N Hor et al. J Cardiovasc Magn Reson. .

Abstract

Background: Steroid use has prolonged ambulation in Duchenne muscular dystrophy (DMD) and combined with advances in respiratory care overall management has improved such that cardiac manifestations have become the major cause of death. Unfortunately, there is no consensus for DMD-associated cardiac disease management. Our purpose was to assess effects of steroid use alone or in combination with angiotensin converting enzyme inhibitors (ACEI) or angiotension receptor blocker (ARB) on cardiovascular magnetic resonance (CMR) derived circumferential strain (εcc).

Methods: We used CMR to assess effects of corticosteroids alone (Group A) or in combination with ACEI or ARB (Group B) on heart rate (HR), left ventricular ejection fraction (LVEF), mass (LVM), end diastolic volume (LVEDV) and circumferential strain (εcc) in a cohort of 171 DMD patients >5 years of age. Treatment decisions were made independently by physicians at both our institution and referral centers and not based on CMR results.

Results: Patients in Group A (114 studies) were younger than those in Group B (92 studies)(10 ± 2.4 vs. 12.4 ± 3.2 years, p < 0.0001), but HR, LVEF, LVEDV and LVM were not different. Although εcc magnitude was lower in Group B than Group A (-13.8 ± 1.9 vs. -12.8 ± 2.0, p = 0.0004), age correction using covariance analysis eliminated this effect. In a subset of patients who underwent serial CMR exams with an inter-study time of ~15 months, εcc worsened regardless of treatment group.

Conclusions: These results support the need for prospective clinical trials to identify more effective treatment regimens for DMD associated cardiac disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Serial ejection fraction (EF) and circumferential strain (εcc). Red, indicates decreased EF and εcc magnitude; blue, indicates increase EF and εcc magnitude and black, indicates mean EF and εcc values. Panels A-C show EF of each subject plotted serially; there was no significant change in mean EF across all three groups. Individually 14/28 (50%) in Group A, 21/31(68%) in Group B and 5/11 (45%) in Group A to B transition had decrease EF, while 14/28 (50%), 10/31 (32%) and 6/11 (55%) of the individuals in the respective groups had increase EF. Panels D-F show εcc of each subject plotted serially; although all three groups had lower absolute εcc on the follow-up study, only Group B subjects had a significant decline (p = 0.007). Individually εcc magnitude decreased more consistently across all three groups, with 24/28 (86%) in Group A, 26/31 (84%) in Group B and 9/11 (82%) in Group A to B. Unlike EF, only a small fraction of the individuals have improvement of εcc magnitude on follow-up study with 4/28 (14%), 5/31 (31%) and 2/11 (18%) of the individuals in the respective group having an increase εcc value on follow-up study.

References

    1. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchene muscular dystrophy locus. 1987. Biotechnology. 1992;24:457–466. - PubMed
    1. Kunkel LM, Monaco AP, Middlesworth W, Ochs HD, Latt SA. Specific cloning of DNA fragments absent from the DNA of a male patient with an X chromosome deletion. Proc Natl Acad Sci USA. 1985;82:4778–4782. doi: 10.1073/pnas.82.14.4778. - DOI - PMC - PubMed
    1. Ray PN, Belfall B, Duff C, Logan C, Kean V, Thompson MW, Sylvester JE, Gorski JL, Schmickel RD, Worton RG. Cloning of the breakpoint of an X;21 translocation associated with Duchenne muscular dystrophy. Nature. 1985;318:672–675. doi: 10.1038/318672a0. - DOI - PubMed
    1. Bushby K, Muntoni F, Urtizberea A, Hughes R, Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord. 2004;14:526–534. doi: 10.1016/j.nmd.2004.05.006. - DOI - PubMed
    1. Finder JD, Birnkrant D, Carl J, Farber HJ, Gozal D, Iannaccone ST, Kovesi T, Kravitz RM, Panitch H, Schramm C. et al.Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med. 2004;170:456–465. - PubMed

Publication types

MeSH terms

Substances